JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BENZ, F. W.
Right arrow Articles by LONG, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BENZ, F. W.
Right arrow Articles by LONG, J. P.
Journal of Pharmacology And Experimental Therapeutics, Vol. 166, Issue 2, 225-236, 1969
Copyright © 1969 by American Society for Pharmacology and Experimental Therapeutics


INVESTIGATIONS ON A SERIES OF HETEROCYCLIC HEMICHOLINIUM-3 ANALOGS

F. W. BENZ 1 and J. P. LONG 1

1 Department of Pharmacology, College of Medicine, The University of Iowa, Iowa City, Iowa

Eight substituted pyridinium and N-methylpiperidinium analogs of hemicholinium-3 were evaluated for their ability to block neuromuscular transmission in the rabbit and to inhibit human erythrocyte acetylcholinesterase. The 3-methylpyridinium and 4-methylpiperidinium derivatives were found to be equipotent to hemicholinium-3 as neuromuscular blockers. The low activity of the 3-methylpiperidinium analog is tentatively explained on the basis of enantiomeric dilution coupled with a possible low yield of the active conformer on quaternization.

Submitted on September 13, 1968
Accepted on December 16, 1968







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics.